Brought to you by 
Cephalon, Alkermes sell Vivitrex in US; ends
03 Dec 2015
Executive Summary
Drug delivery company Alkermes has licensed Cephalon (therapeutics for neurological diseases and cancer) US development and commercialization rights to Vivitrex, its naltrexone once-monthly injection, which is under FDA review to treat alcohol dependence.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com